Chronic obstructive pulmonary disease: Consensus recommendations for early diagnosis and treatment

Journal of Family Practice

Volumn 55, Issue 11, 2006, Pages

  Doherty, Dennis E ^a   Belfer, Mark H ^b,c   Brunton, Stephen A ^d   Fromer, Leonard ^e   Morris, Charlene M ^f   Snader, Thomas C ^g,h  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c AKRON GENERAL MEDICAL CENTER   (United States)

^d AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Halyburton Naval Hospital   (United States)

^g UNIVERSITY OF THE SCIENCES   (United States)

^h TCS Pharmacy Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID; INFLUENZA VACCINE; INTERLEUKIN 4; INTERLEUKIN 8; IPRATROPIUM BROMIDE; LEUKOTRIENE; LEUKOTRIENE B4; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; NEDOCROMIL; OPIATE DERIVATIVE; OXYGEN; PHOSPHODIESTERASE; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONSENSUS; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EARLY DIAGNOSIS; FORCED EXPIRATORY VOLUME; GRAND MAL SEIZURE; HEADACHE; HEART ARRHYTHMIA; HEARTBURN; HUMAN; INHALER; INSOMNIA; LUNG INJURY; NAUSEA; OXYGEN THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SMOKING; SMOKING CESSATION; SPIROMETRY; SYMPTOM; UNSPECIFIED SIDE EFFECT;

EID: 33750983645     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Centers for Disease Control and Prevention website. Chronic obstructive pulmonary disease. Available at: http://www.cdc.gov/nceh/airpollution/copd/ copdfaq.htm. Accessed August 1, 2006.
2. National Lung Health Education Program website. Frequently asked questions. Available at: http://www.nlhep.org/faqs.ntml. Accessed August 1, 2006.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.org/ Guidelineitem.asp?l1= 2&l2=1&intId=989. Accessed July 28, 2006.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper: Eur Respir J. 2004;23:932-946.
5. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest. 2000;117:1146-1161.
6. The National Institute for Clinical Excellence. British Thoracic Society COPD Consortium. NICE COPD Guidelines 2004. Available at: http://www.brit- thoracic.org.uk/copd/latest_frameset_nice.html. Accessed May 3, 2006.
7. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2003. Can Respir J. 2003;10(suppl A):11A-65A.
8. National Center for Health Statistics website. National vital statistics reports. Deaths. Final data for 2003. Available at: http://www.cdc.gov/nchs/ data/nvsr/nvsr54/nvsr54_13.pdf. Accessed August 1, 2006.
9. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care. 2003;48:1185-1191.
10. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001;17:982-994.
11. The National COPD Awareness Panel. Guidelines for early detection and management of COPD. J Respir Dis. 2000;21(suppl):S5-S21.
12. Doherty DE. The pathophysiology of airway dysfunction. Am J Med. 2004;117(suppl 12A):11S-23S.
13. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339:1194-1200.
14. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis, 1987;70:171-179.
15. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004;59(suppl 1):1-232.
16. Doherty DE. Early detection and management of COPD. What you can do to reduce the impact of this disabling disease. Postgrad Med. 2002;111:41-50, 53.
17. Ahluwalia JS, Gibson CA, Kermey RE, Wallace DD, Resnicow K. Smoking status as a vital sign. J Gen Intern Med. 1999;14:402-408.
18. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clin Proc. 1995;70:209-213.
19. Doherty DE. COPD: an approach for primary care prevention. Federal Forum. 2002;Nov(suppl):15-21.
20. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ. 1959;2:257-266.
21. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-1012.
22. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618-2625.
23. Sayiner A, Aytemur ZA, Grit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119:726-730.
24. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941-1947.
25. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778-784.
26. Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health. 1998;52:120-125.
27. Simberkoff MS, Cross AP, Al Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;315:1318-1327.
28. California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J Cardiopulm Rehabil. 2004;24:52-62.
29. Goldstein RS, Gort EH, Guyatt GH, Feeny D. Economic analysis of respiratory rehabilitation. Chest. 1997;112:370-379.
30. Verrill D, Barton C, Beasley W, Lippard WM. The effects of short-term and long-term pulmonary rehabilitation on functional capacity, perceived dyspnea, and quality of life. Chest. 2005;128:673-683.
31. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748.
32. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
33. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2002;110(suppl):S298-S303.
34. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.
35. Oostenbrink JB, Rutten-van Molken MP, Al MJ, van Noord JA, Yincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241-249.
36. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168-1178.
37. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840.
38. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86-94.
39. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 1989;320:1521-1525.
40. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289-294.
41. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411-1419.
42. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784.
43. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
44. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326.
45. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-404.
46. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once-daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214-222.
47. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121:1058-1069.
48. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283-1289.
49. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000;15:878-885.
50. US Food and Drug Administration website. FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluricasone propionate & salmeterol xinafoate powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Available at: http://www.fda.gov/cder/ drug/advisory/laba.htm. Accessed January 20, 2006.
51. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112:1514-1521.
52. ZuWallack RL, Mahler DA, Reilly D, et al. Saimeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:16614670.
53. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration. 1998;65:354-362.
54. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-817.
55. Calverley P, Pauwels R, Vestbo J, et al. Combined saimeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449-456.
56. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-1091.
57. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
58. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698-702.
59. Francis RS, May JR, Spicer CC. Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its Bronchitis Subcommittee. Br Med J. 1961;2:979-985.
60. Francis RS, Spicer CC. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. Er Med J. 1960;1:297-303.
61. Petty TL, The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest. 1990;97:75-83.
62. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest. 1987;92:618-620.
63. Poole P, Black P. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;3:CD001287.